Topic Listing for Celgene

Accounting Tax Considerations Acquisitions
Administration Amendment Termination
Annual Meeting Annual Report Form 10-k
Approval Amendment Restatement 1998 Stock Incentive Plan Arthur Hull Hayes
Audit Committee Pre-approval Permissible Non-audit Services Independent Registered Audit Committee Report
Audit Committee Report Stockholders Audit Fees
Audit-related Fees Background
Background Proposal Amend 1998 Stock Incentive Plan Background Proposal Amend Directors Incentive Plan
Background Proposal Approve Amendment Restatement Plan Barer Hugin
Base Salary Beneficial Ownership Reporting Compliance
Board Directors Unanimously Recommends Vote Election Each Nominees Board Independence
Board Meetings Committees Membership Bonus Performance Based Incentive Compensation
Cash Bonus Performance-based Incentive Compensation Cash Performance-based Incentive Compensation
Celgene Corporation Celgene Corporation Morris Avenue Summit New Jersey 07901
Celgene Leading Product Candidates Certain Federal Income Tax Consequences
Certain Other Tax Issues Certification Pursuant Usc Sec 1350 Adopted 302 Sarbanes-oxley
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Change Control
Changes Effective Income Tax Rate Impact Earnings Changes Internal Controls Over Financial Reporting
Code Ethics Commercial Stage Products
Common Stock Comparison Cumulative Total Return
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Discussion Analysis Compensation Philosophy
Competition Conclusion Regarding Effectiveness Disclosure Controls Procedures
Consent Independent Registered Public Accounting Firm David Gryska
David Gryska Aart Brouwer Deferred Compensation Plan
Delivery Documents Stockholders Sharing Address Determination Appropriate Pay Levels
Director Compensation Documents Incorporated Reference
Electronic Notice Mailing Employees
Employment Agreements Employment Agreements Termination Arrangements
Entered Definitive Agreement Acquire Pharmion Subject Certain Closing Equity Compensation Plan Information
Ernest Mario Phd Exact Name Registrant Specified Charter
Exchange Act 1934 Executive Compensation Policies Programs
Executive Officers Experience Adverse Market Reaction Unable Meet Financial Reporting
Experience Significant Fluctuations Quarterly Operating Results Factors Affecting Future Results
Fas 123r Form 10-k
Gilla Kaplan Phd Governmental Regulation
Graham Burton Grown Rapidly Fail Adequately Manage Growth Business Adversely
Hazardous Materials Research Development Other Business Operations Result Http Wwwcelgenecom
Incentive Stock Options Index Consolidated Financial Statements
International Operations Internet
Introduction James Loughlin
John Jackson List Subsidiaries
Litigation Variety Matters Subject Significant Legal Expenses Liability Mail
Managements Report Internal Control Over Financial Reporting Manufacturing
Market Price Dividends Registrants Common Equity Related Stockholder Messrs Gryska Brouwer Burton
Michael Casey Minimum Stock Ownership Requirements
New Accounting Principles New Plan Benefits
Nominees Nonqualified Stock Options
Not Able Protect Intellectual Property Products Subject Generic Notice Annual Meeting Stockholders
Number Shares Common Stock Eligible Future Sale Adversely Operations Impacted Currency Fluctuations Cause Earnings Fluctuate
Option Exercises Stock Vested Table Option Exercises Values 2004
Option Voting Proxy Via Internet Wwwproxyvotecom Toll Free Other Fees
Other Matters Other Stock-based Awards
Outstanding Equity Awards Value Year-end Table Overview Compensation Committee
Overview Compensation Program Part
Parties Rely Fail Produce Timely Basis Encapsulation Finishing Patents Proprietary Technology
Performance Graph Performance-based Awards
Perquisites Other Personal Benefits Person
Pharmaceutical Biotech Industry Highly Competitive Subject Rapid Significant Pharmaceutical Industry Subject Extensive Government Regulation Presents Numerous
Policy Respect Compensation Deductibility Potential Payments Termination Change Control
Preclinical Clinical Stage Pipeline Price Common Stock Fluctuate Significantly Make Difficult Sell
Principal Accountant Fees Services Process Establishing Foreign Marketing Distribution Capabilities
Products Not Accepted Market Demand Deteriorate Materialize Proposal Registered Public Accounting Firm
Proxy Solicited Behalf Board Directors Proxy Statement
Purpose Eligibility Record Date Voting Securities
Registered Public Accounting Firm Registrants Telephone Number Including Area Code
Report Independent Registered Public Accounting Firm Restricted Stock
Retirement Other Benefits Review Approval Transactions Related Persons
Revocability Proxies Richard Morgan
Robert Hugin Rodman Drake
Sales Commercialization Sales Products Dependent Third-party Reimbursement
Schedule 14a Rule 14a-101 Information Required Proxy Statement See Reverse Side Meeting Information Instructions Vote
Service Employment Agreements Sfas 123r
Share Based Payment Share Other Limitations
Shareholder Rights Plan Certain Charter By-law Provisions Deter Signatures Power Attorney
Significant Alliances Sol Barer Phd
Solicitation Expenses Stock Appreciation Rights Sars
Stock Option Awards Stock Option Grants 2004
Stock Option Grants Incentive Plan Stock Options
Stockholder Communications Stockholder Nominations
Stockholder Proposals Summary 1998 Stock Incentive Plan
Summary Directors Incentive Plan Summary Plan Amended Restated
Tax Fees Telephone
Timing Compensation Title Class
Transferability Types Awards
Unable Retain Skilled Personnel Maintain Key Relationships Unsuccessful Developing Commercializing Products Business Financial Condition Results
Vote Vote Via Internet Telephone Not Mail Proxy Card
Voting Procedures Abstentions Walter Robb Phd
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki